Churchill Pharmaceuticals

Uro Pipeline: Phase IIb study begins for intraprostatic localized PCa drugOther pipeline developments include a new company formed to develop OAB treatments, a phase III urothelial cancer study meeting its primary endpoint, the formation of a partnership to study RCC treatment, and more.